Summary of COVID-19 diacerein studies

1. Carmo et al., Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study

14 patient diacerein late treatment RCT: 10% longer hospitalization (p=0.79).
RCT 14 hospitalized patients with mild to moderate COVID-19 showing reduced plasma inflammasome markers with diacerein treatment, but no significant difference in duration of hospitalization. The study was halted early due to declining COVID-19 hospitalizations, limiting statistical power.
Oct 2024, Frontiers in Pharmacology, https://www.frontiersin.org/articles/10.3389/fphar.2024.1402032/full, https://c19p.org/carmo